RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Thanks Neuro. For ADHD, Takeda would be much better off with a low impact. I'll have to check out their patents, but they're most likely using a high impact. Dr. Rogers said it was very unlikely that another company would ever be able to develop low impacts, in part because the low impact mechanism is so difficult to screen compounds for due to the low signal, and also because the high impacts hold the promise of reversing neurodegeneration via upregulating BDNF. But ADHD doesn't require BDNF upregulation, and trying to use a high impact for ADHD is not a good fit.

As we know, Cortex has an array of new generation low impacts just waiting to be partnered, with strong efficacy in ADHD already demonstrated in Phase 2 by CX-717, before the artifact derailed its development.

It's ironic that the 'ultra safe' low impacts got derailed, while the seizure prone high impacts continued to be developed by other companies. Dr. Stoll said Cortex had achieved a major breakthrough with the newest generation of high impacts, but unfortunately weren't able to bring them into the clinic due to lack of funds. Those compounds, and the new low impacts, are all still available, so maybe the bio winds of fate will finally change for Cortex.